| 40.6 2.83 (7.49%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 47.52  |
1-year : | 55.51 |
| Resists | First : | 40.68 |
Second : | 47.52 |
| Pivot price | 36.1 |
|||
| Supports | First : | 34.6 |
Second : | 30.85 |
| MAs | MA(5) : | 37.77 |
MA(20) : | 35.58 |
| MA(100) : | 30.97 |
MA(250) : | 32.45  |
|
| MACD | MACD : | 1.9 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 82.1 |
D(3) : | 74.8 |
| RSI | RSI(14): 67.5 |
|||
| 52-week | High : | 62.5 | Low : | 18.92 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VKTX ] has closed above the upper band by 3.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 6.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 40.74 - 40.89 | 40.89 - 41.01 |
| Low: | 36.68 - 36.86 | 36.86 - 37 |
| Close: | 40.31 - 40.61 | 40.61 - 40.85 |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Tue, 11 Nov 2025
William Blair Reiterates “Buy” Rating on Viking Therapeutics (VKTX) Following New VK2735 Data - MSN
Mon, 10 Nov 2025
William Blair Reiterates “Buy” Rating on Viking Therapeutics (VKTX) Following New VK2735 Data - Insider Monkey
Mon, 10 Nov 2025
Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. Next Big Pharma Target? - TipRanks
Thu, 06 Nov 2025
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025 - PR Newswire
Sun, 02 Nov 2025
Sell Novo Nordisk And Buy Viking Therapeutics (NASDAQ:VKTX) - Seeking Alpha
Mon, 27 Oct 2025
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 113 (M) |
| Shares Float | 111 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 67.7 (%) |
| Shares Short | 25,450 (K) |
| Shares Short P.Month | 27,010 (K) |
| EPS | -2.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.5 % |
| Return on Equity (ttm) | -29.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -225 (M) |
| Levered Free Cash Flow | -151 (M) |
| PE Ratio | -19.16 |
| PEG Ratio | 0 |
| Price to Book value | 6.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -20.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|